Phase II trial of thymosin beta-4 [RGN 352] for the treatment of patients immediately following an acute myocardial infarction

Trial Profile

Phase II trial of thymosin beta-4 [RGN 352] for the treatment of patients immediately following an acute myocardial infarction

Suspended
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2011

At a glance

  • Drugs Thymosin-beta-4 (Primary)
  • Indications Myocardial infarction
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Oct 2011 This trial is still on clinical hold, according to a RegeneRx media release.
    • 17 Mar 2011 The US FDA has placed a clinical hold on this trial due to non-compliance of cGMP at a contract manufacturing site.
    • 11 Feb 2011 Status changed from planning to not yet recruiting, based on a RegeneRx Biopharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top